The Asia Pacific T-Cell therapy Market should witness market growth of 18.5% CAGR during the forecast period (2023-2030).
T-cell-based methods are widely used in the discipline of cancer immunotherapy now due to their higher success rate. The expanding field of gene therapy has a significant impact on the efficacy of CAR T therapies. The growing investment will probably lead to further expansion of the gene therapy sector. However, because of CAR T-cell therapy, some cancer cells can be made by scientists to be more easily found and eliminated by T-cells. The requirement for CAR T-cell therapy will therefore be driven in the near future by the predicted rise in cancer patients.
Although HICs have higher overall rates of cancer incidence, LMICs have much higher death rates and total cancer-related mortality rates, which are also continuing to grow, compared to HICs, where mortality rates are either falling or remaining stable. Hence, the acceptance of T-cell therapies is anticipated to be fueled in the coming years by increased manufacturer promotional efforts and a rise in public knowledge of effective cancer treatment pharmaceuticals.
The most frequent type of leukemia in children is acute lymphoblastic leukemia. There have been improvements in treating this disease, and research is ongoing to produce even better results. Like the West, India is seeing an increase in the percentage of ALL cured children. Numerous Indian research has suggested that patients have more high-risk factors. Despite the lack of information regarding cytogenetics in India, a higher percentage of children have unfavorable cytogenetics. Since the region has many children, the demand for T-cell therapies is anticipated to increase. For example, according to a recent projection by the United Nations International Children's Emergency Fund, India approximately had 444 million children (aged 0 to 18) in 2022. Hence, all these factors are promoting the growth of the regional market.
The China market dominated the Asia Pacific T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $683.9 million by 2030. The Japan market is exhibiting a CAGR of 17.8% during (2023-2030). Additionally, The India market would showcase a CAGR of 19.3% during (2023-2030).
Based on End-user, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
T-cell-based methods are widely used in the discipline of cancer immunotherapy now due to their higher success rate. The expanding field of gene therapy has a significant impact on the efficacy of CAR T therapies. The growing investment will probably lead to further expansion of the gene therapy sector. However, because of CAR T-cell therapy, some cancer cells can be made by scientists to be more easily found and eliminated by T-cells. The requirement for CAR T-cell therapy will therefore be driven in the near future by the predicted rise in cancer patients.
Although HICs have higher overall rates of cancer incidence, LMICs have much higher death rates and total cancer-related mortality rates, which are also continuing to grow, compared to HICs, where mortality rates are either falling or remaining stable. Hence, the acceptance of T-cell therapies is anticipated to be fueled in the coming years by increased manufacturer promotional efforts and a rise in public knowledge of effective cancer treatment pharmaceuticals.
The most frequent type of leukemia in children is acute lymphoblastic leukemia. There have been improvements in treating this disease, and research is ongoing to produce even better results. Like the West, India is seeing an increase in the percentage of ALL cured children. Numerous Indian research has suggested that patients have more high-risk factors. Despite the lack of information regarding cytogenetics in India, a higher percentage of children have unfavorable cytogenetics. Since the region has many children, the demand for T-cell therapies is anticipated to increase. For example, according to a recent projection by the United Nations International Children's Emergency Fund, India approximately had 444 million children (aged 0 to 18) in 2022. Hence, all these factors are promoting the growth of the regional market.
The China market dominated the Asia Pacific T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $683.9 million by 2030. The Japan market is exhibiting a CAGR of 17.8% during (2023-2030). Additionally, The India market would showcase a CAGR of 19.3% during (2023-2030).
Based on End-user, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
Scope of the Study
By End-user
- Hospitals
- Cancer Treatment Centers
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Others
By Therapy Type
- CAR T-Cell Therapy
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
- T-Cell Receptor (TCR)-Based
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific T-Cell therapy Market by End User
Chapter 5. Asia Pacific T-Cell therapy Market by Indication
Chapter 6. Asia Pacific T-Cell therapy Market by Therapy Type
Chapter 7. Asia Pacific T-Cell therapy Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Methodology
LOADING...
![Asia Pacific T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors) - Product Image](http://www.researchandmarkets.com/product_images/12628/12628862_60px_jpg/asia_pacific_t_cell_therapy_market_forecast.jpg)
![T Cell Therapy Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type [CAR T-cell Therapy and T-cell Receptor-based], Indication, and Geography - Product Image](http://www.researchandmarkets.com/product_images/12573/12573998_60px_jpg/market_research_report.jpg)
